Why Life Sciences Requires Data Experts For Business Insights

This article discusses the crucial need for data experts in life sciences who bridge technical skills and business understanding. By aligning data projects with business goals, they enhance decision-making and improve patient outcomes.

In the life sciences industry, where the stakes range from billion-dollar health care pipelines to individual patient outcomes, data is everywhere. But simply having access to data isn't enough. Data has to be used for better decision-making, and a growing realization is that, along with appropriate technical skills, one also needs to understand the needs of the business end-to-end.

Pinaki Bose, a data and analytics leader who has worked across pharmaceutical and medical device organizations to bridge the gap between raw data and real-world value, is working on this path.

Bose's journey through the industry includes leading initiatives to integrate siloed data systems into cohesive platforms that serve cross-functional needs. In medical devices and pharma alike, he has helped develop strategic capabilities using market share analytics and competitive intelligence. In one key example, his efforts enabled global business insights that allowed executives to shape decisions with a better understanding of the competitive landscape.

He also enabled more strategic prioritization of analytical projects by connecting data insights directly to key business metrics like R&D efficiency and revenue growth, and improved the accuracy of problem identification and the effectiveness of solution design by embedding deep business context into data initiatives. For example, understanding regulatory implications for data points led to more robust collection and analysis methods.

Apart from data output, he acted as a key liaison between technical teams and various business units (e.g., R&D, Clinical Operations, Commercial), facilitating effective communication and promoting data literacy that moved beyond data output to deliver solutions that optimized business pipelines.

In pharmaceutical R&D, he played a critical role in global clinical planning and forecasting dataset infrastructure. These datasets are now used by multiple stakeholders from diverse business sections within Pharma R&D.

One of Bose's key strengths lies in his deep integration with business strategy. He has consistently demonstrated that understanding the context behind the numbers leads to more impactful insights. By aligning data projects with business objectives, like improving patient outcomes, optimizing trial costs, or enhancing market access, he ensures that analytics are not isolated but embedded in decision-making processes.

His impact is quantifiable. Projects he has led have resulted in a 15–20% reduction in project scope creep, as a better understanding of business needs early on helped align technical output more closely with expectations. He's also driven a 20–25% improvement in time-to-insight, meaning critical business decisions can now be informed more quickly and accurately. Notably, the user adoption rate for analytical tools and dashboards he's implemented has seen a 10–15% uptick, thanks to better alignment with actual business workflows and user needs.

However, these contributions had certain considerations. The most persistent one? Bridging the divide between data and business is a gap that has stymied many analytics efforts in the sector. His ability to act as a liaison between business units and technical teams has helped improve collaboration and data literacy across the board. He's also led efforts to unify disparate data silos, which remain a structural hurdle in many large life sciences organizations. In doing so, he's helped establish a more accessible data infrastructure.

Another challenge he's tackled is compliance in regulated environments. Understanding frameworks like GxP and country-specific rules, he's ensured that data strategies are compliant by design, reducing risk and preventing costly delays in areas like clinical trials or product launches. One more important challenge that he had to tackle was shifting the focus from data output to business value, guiding the team and stakeholders to move beyond generating reports or models and identify high-impact analytical opportunities that directly optimized operational efficiencies and strategic outcomes.

Among his most impactful projects, where he has contributed, are market share analytics and competitive intelligence initiatives that have guided strategy for global medical device portfolios and the creation of end-consumption layers for R&D datasets that are now embedded across pharma divisions for planning, forecasting, and operational decision-making.

When asked about some insights on the field, from his vantage point, he tells us that the future of life sciences analytics lies not in better tools, but in better context. "My core insight is that true data expertise in Life Sciences is increasingly less about technical prowess alone and profoundly more about an end-to-end understanding of the business," he says.

He further talks about the context, “The rapid evolution of Generative AI and Agentic AI reinforces this perspective. As these technologies automate more mundane technical activities, the demand for unique creativity derived from rare insights into business processes will surge. In a domain as critical as Life Sciences, where human lives are at stake, this deep understanding is not just beneficial, but critical for ensuring data integrity, ethical application, and meaningful innovation.”

Hyper-personalized medicine is emerging through the integration of genomic, behavioural, and clinical data, alongside a nuanced understanding of market and regulatory frameworks. Predictive clinical trials are gaining momentum, with advanced analytics improving everything from participant recruitment to outcome forecasting. On the research front, AI and integrated data are driving proactive drug discovery, allowing scientists to pinpoint promising therapeutic targets far earlier than traditional methods.

As treatments advance, optimized market access, powered by end-to-end business insights to design highly effective market access strategies and patient engagement programs, is ensuring that life-saving therapies reach patients more quickly. At the same time, intelligent regulatory navigation is becoming a key enabler, as AI-driven systems streamline compliance processes from the very beginning.

His message is clear: in life sciences, the art of data is the art of understanding the business requirements. And for organizations to thrive in this next chapter, they'll need more experts who can translate bytes into business value, from molecule to market.